Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF (XLV) each adding 1.2%.

The iShares Biotechnology ETF (IBB) increased 0.2%.

In sector news, UroGen Pharma's (URGN) investor event reinforced the commercial thesis for Zusduri in low-grade intermediate-risk non-muscle invasive bladder cancer, with the physician panel suggesting that peers may face tough competition unless they can offer overwhelmingly better efficacy, Oppenheimer said in a note. UroGen shares were down 0.5%.